Kronos Bio(KRON.US) Officer Buys US$733.8K in Common Stock
$Kronos Bio(KRON.US)$ Officer BISCHOFBERGER NORBERT W purchased 615.52K shares of common stock on Jun 27, 28, 2024 at an average price of $1.1922 for a total value of $733.8K.Source: Announcement What
Shareholders May Be More Conservative With Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For Now
Increases to Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation Might Cool off for Now
Key Insights Kronos Bio to hold its Annual General Meeting on 25th of June Total pay for CEO Norbert Bischofberger includes US$580.0k salary The total compensation is 55% higher than the average f
President of Kronos Bio Picks Up 36% More Stock
Kronos Bio, Inc. (NASDAQ:KRON) shareholders (or potential shareholders) will be happy to see that the President, Norbert Bischofberger, recently bought a whopping US$3.1m worth of stock, at a price of
Insider Spends US$3.1m Buying More Shares In Kronos Bio
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersLongeveron (NASDAQ:LGVN) stock increased by 74.6% to $3.16 during Thursday's regular session. The company's market cap stands at $20.0 million. BioRestorative Therapies (NASDAQ:BRTX) stock rose
Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders inte
Kronos Bio(KRON.US) Officer Buys US$3.12 Million in Common Stock
$Kronos Bio(KRON.US)$ Officer BISCHOFBERGER NORBERT W purchased 3.01 million shares of common stock on Jun 10, 11, 12, 2024 at an average price of $1.0379 for a total value of $3.12 million.Source: An
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersElutia (NASDAQ:ELUT) stock rose 24.2% to $4.31 during Tuesday's regular session. The market value of their outstanding shares is at $104.9 million. Trinity Biotech (NASDAQ:TRIB) stock rose 20.6
Here's Why We're Watching Kronos Bio's (NASDAQ:KRON) Cash Burn Situation
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed — — KB-0742 continues to show dose linear pharmacokinetics up to 80mg three-days-on, four-days-off
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by
Kronos Bio Hires Ex-Senti Bio CFO to Head Finances, Operations
By Dean Seal Kronos Bio has hired the former chief financial officer of Senti Bio to helm its finances and also serve as chief operating officer. The biotechnology company said Tuesday that Deborah
Express News | Kronos Bio Appoints Deborah Knobelman As COO And CFO, EFfective Jun. 3
Kronos Bio: Knobelman 'S Appointment Effective June 3 >KRON
Kronos Bio: Knobelman 'S Appointment Effective June 3 >KRON
Express News | Kronos Bio Appoints Deborah Knobelman, Ph.d. as Chief Operating Officer and Chief Financial Officer
Vicore Expands and Strengthens Its Board of Directors
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of
Optimistic Buy Rating for Kronos Bio Amid Positive KB-0742 Trial Progress and Expanding Oncology Pipeline
Express News | Kronos Bio Inc: $152.0 Mln in Cash, Cash Equivalents and Investments as of March 31, 2024
Express News | Kronos Bio Inc: Anticipates Sufficient Resources to Fund Its Planned Operations Into Second Half of 2026